US companies link up to target Europe with cancer immunotherapy

Medical technology company Terumo Blood and Cell Technologies and Immunicom, a biotech pioneering subtractive immunotherapies, have signed a co-commercialization agreement.

The US firms have teamed up to advance a cancer therapy that selectively removes immune inhibitors from a patient’s bloodstream. This potentially enables the immune system to more effectively attack tumors.

"Imagine if someone who is battling late-stage breast cancer could mitigate the effects of chemotherapy"Unlike immunotherapy pharmaceuticals, which introduce foreign compounds into the body and can come with negative side effects, Immunicom’s technology is based on a subtractive approach that is intended to limit adverse effects.